Australia - English - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 172.69 mg (equivalent: quetiapine, qty 150 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium citrate dihydrate; lactose monohydrate; hypromellose; titanium dioxide; magnesium stearate; macrogol 400 - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 57.56 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - donepezil hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - donepezil hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -